Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance its mission of using the power of science to bring new medicines to patients in need.
The Regeneron GCC is expected to grow to hundreds of jobs in the coming years as it expands capabilities across key global functions. Founded and led by physician-scientists, Regeneron is a global biotechnology leader headquartered in the United States (US) with 15 approved or authorised medicines and nearly 50 pipeline candidates spanning multiple therapeutic areas.
The Regeneron GCC is expected to further strengthen Hyderabad’s position as a leading life sciences and GCC destination. With over 450 GCCs, Hyderabad offers access to a strong talent pool across biotechnology, life sciences, AI, digital technologies and analytics, supported by a mature innovation ecosystem, robust infrastructure and strong research capabilities.
Expected to be operational in the second half of 2026, the site is planned to scale to hundreds of new roles in the coming years.
Regeneron established its Bengaluru presence in 2022. The Regeneron GCC builds on that foundation by expanding the company’s global operations and reinforcing India’s role as a long-term strategic partner for its growth.
